Product Launch Formula 2.0 Bonus

Posts Tagged ‘Oral Treatment’

New Data From CLARITY Study on Disease Activity in MS Patients who Received Cladribine Tablets Presented at 25th ECTRIMS Congress DÜSSELDORF, Germany and GENEVA, September 11/PRNewswire/ – - Post-hoc Analysis From CLARITY Study Show That Short-Course Oral Treatment With Cladribine Tablets Significantly Increased the Proportion of Patients who had Absence of Disease Activity Compared With Placebo Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced new data from a post-hoc